Frontiers in Molecular Biosciences · 2021 · 12 citations · 35 references
Life SciencesImmunologyOncologyApoptosisCancer ImmunologyImmunotherapyCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyCytotoxic T Lymphocyte ResponsesDeath ReceptorsReceptor-mediated TargetingTargeted Cancer TherapyProgrammed Death-ligand 1 TargetingReceptor-mediated ApoptosisSingle-chain Variable FragmentsT Cell CytotoxicityT Cell-mediated CytotoxicityTrail ReceptorsTrail-mediated ApoptosisTumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors
Tumor necrosis factor–related apoptosis-inducing ligand receptor 1 (TRAIL-R1) has limited expression in normal tissues but was highly expressed in various types of tumors, making it an attractive target for cancer immunotherapy. Here, we utilized the single-chain variable fragment (scFv) from our previously identified TRAIL-R1–targeting monoclonal antibody (TR1 419 ) with antitumor efficacy and produced the TR1 419 chimeric antigen receptor (CAR) T cells. We characterized the phenotypes and functions of these CAR-T cells and found that the third-generation TR1 419 -28BBζ CAR-T cells exhibited greater target sensitivity and proliferative capability, with slightly higher PD-1 expression after antigen stimulation. Importantly, we found that the TR1 419 CAR-T cells could induce TRAIL-R1–positive tumor cell death via a dual mechanism of the death receptor–dependent apoptosis as well as the T-cell–mediated cytotoxicity. Altogether, the TR1 419 CAR-T cells could serve as a promising strategy for targeting the TRAIL-R1–positive tumors.
35
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text
Medicine, Immunology, Oncology +17
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17